Parmax Pharma Limited has submitted a regulatory disclosure to BSE Limited regarding an upcoming board meeting. The meeting of the Board of Directors is scheduled to be held on Friday, August 14, 2026. The primary purpose of this meeting is to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27).